OUR MISSION
WHO WE ARE
Innovating Regenerative Medicine
From Academic Innovation To Transformative Therapeutics
Academic Origin
Spun out from The Chinese University of Hong Kong (CUHK) in 2023
Therapeutic Focus
Developing first-in-class cytokine-based therapies for vascular diseases
Expert Team
Over 40% R&D scientists with translational and commercial expertise
Ecosystem Support
Accelerated by CUHK and HKSTP programs, funded by Hong Kong ITF
OUR MISSION
AI & Regenerative Medicine
Breakthrough Science
Developing breakthrough type2 cytokine and cell-based treatments
AI-Driven Discovery
AI‑accelerated therapeutic protein development
Breakthrough
Streamlining and cheaper antibody/protein therapies
Platform Evolution
Focused on endothelial health and mechanism of action
Targeted Impact
Precision treatments for ischemic vascular disease
Ultimate Goal
Delivering accessible regenerative medicines & improving quality of life
KEY MILESTONES & METRICS
Progress In Action
TEAM MEMBERS
0
PRECLINICAL PIPELINES
0
R&D TEAM
0
%
